Katina Dorton (AvroBio Inc. (Nasdaq: AVRO))

Dorton, Katina (AvroBio 201709– CFO before Immatics + Needham & Co + Morgan Stanley + Sullivan & Chromwell)

	Organisation	Immatics Biotechnologies GmbH
	Group	Immatics (Group)
	Product	gene therapy
	Product 2	investment banking

AvroBio, Inc.. (9/26/17). "Press Release: AvroBio, Inc. Appoints Katina Dorton as Chief Financial Officer". Cambridge, MA.

AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, announces today the appointment of Katina Dorton as Chief Financial Officer.

“I am delighted to welcome Katina to the AVROBIO team,” said Geoff MacKay, AVROBIO’s President and Chief Executive Officer. “Katina comes to us with extensive experience in biotechnology, capital markets and strategic corporate transactions. I am confident that she will be of great value to AVROBIO as we continue to grow and develop our gene therapy programs.”

“AVROBIO is an exciting, innovative gene therapy company with tremendous potential,” added Ms. Dorton. “I share its commitment to become a leading gene therapy company and bringing forward important therapies for the patients we are serving. I look forward to working with the remarkable team at AVROBIO and the strong existing investor base.”

Ms. Dorton brings more than 20 years of investment banking experience and has served as a senior strategic and financing advisor to numerous companies in the life sciences and biotechnology sectors. Prior to joining AVROBIO, Ms. Dorton served as Chief Financial Officer of Immatics GmbH. She is a former Managing Director, Morgan Stanley in New York and Frankfurt, Germany, serving 12 years at the firm. Prior to her investment banking career Ms. Dorton was an attorney in private practice with Sullivan & Cromwell. Ms. Dorton holds a J.D. from the University of Virginia School of Law, an M.B.A. from George Washington University and a B.A. from Duke University.

About AVROBIO, Inc.

AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical-stage company developing disruptive therapies that have the potential to transform patients’ lives with a single dose. The Company is focused on the development of its Phase 1 program in Fabry disease and pre-Phase 1/2 program in Gaucher disease, while actively building a pipeline of therapies to treat Pompe disease and other rare and non-rare genetic diseases. AVROBIO also has an immuno-oncology gene therapy program. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON. For additional information, visit www.avrobio.com.

Media Inquiries:

Kirsten Dupuis
AVROBIO, Inc.
+1.617.914.8403
kirsten.dupuis@avrobio.com

Record changed: 2020-06-26

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for Katina Dorton

[1] AvroBio, Inc.. (9/26/17). "Press Release: AvroBio, Inc. Appoints Katina Dorton as Chief Financial Officer". Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)